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Abstract 
Aim: Anti-psychotic medication has been the mainstay of treatment for psychotic illnesses for over 
60 years. This has been associated with improvements in positive symptoms and a reduction in 
relapse rates. However, there has been little improvement in functional outcomes for people with 
psychosis. At the same time there is increasing evidence that medications contribute to life 
shortening metabolic and cardio-vascular illnesses. There is also uncertainty as to the role played by 
anti-psychotic medication in brain volume changes.  
Aim: The primary aim of the study is to compare functional outcomes at 24-months between an 
anti-psychotic dose reduction strategy with evidence based intensive recovery treatment (EBIRT) 
(DRS+) and an antipsychotic maintenance treatment with EBIRT (AMTx+). 
Methods: A single-blind randomized controlled trial will test the whether a dose reduction strategy 
in combination with our evidence based intensive recovery treatment (DRS+),+  leads to better 
vocational and social recovery than continuous antipsychotic maintenance treatment in combination 
with evidence based intensive recovery treatmeAMTx+)+ over a 2-year period in 180 remitted first 
episode psychosis (FEP) patients. Additionally, we will examine the effect of DRS+ vs AMTx+ on 
physical health, brain volume and cognitive functioning. In terms of safety thisThis study will also 
determine whether those receiving DRS+ will be no worse off in terms of psychotic relapses over 2 
years follow up. 
Results: This paper presents the protocol, rationale and hypotheses for this study which commenced 
recruitment in July 2017. 
Conclusion: This study will test whether an alternativeantipsychotic dose-reduction recovery 
treatment leads to improved functioning and safer outcomes in FEP patients. It will also be the first 
controlled experiment of the effect of exposure to antipsychotic maintenance treatment on brain 
volume changes in this population. 
 
Key words: 
First-episode psychosis 
Functional recovery 
Dose reduction  
Anti-psychotic medication 
Protocol 
  
Page 4 of 65Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Dose reduction in FEP: Study Protocol  
 
4 
 
Introduction 
It is over 65 years since antipsychotic medications were introduced and became the mainstay of 
treatment for psychotic illnesses. There has undoubtedly been many benefits of their use in the 
control of symptoms, particularly positive symptoms of psychotic illness, and the reduction of 
relapse rates (Addington, Killackey, & Marulanda, In Press). Despite this, and even with the 
introduction of second generation antipsychotic medication there has been little indication that 
people with psychotic illness have returned to functional roles in any great number. For example, 
people diagnosed with psychotic (Eóin Killackey & Allott, 2013)illnesses are less likely to complete 
their secondary education(Waghorn et al., 2012) and unemployment remains a highly prevalent 
problem associated with the disorder. Loneliness is also a significant issue for young people with 
psychosis, so much so that the onset of psychosis has been characterised as a social network crisis 
which is not ameliorated by current interventions(Horan, 2006). In a range of other functional 
domains, housing security,(Harvey, Killackey, Groves, & Herrman, 2012) physical health(V. Morgan et 
al., 2013), and social relationships and engagement in community(V. A. Morgan et al., 2011), people 
with psychotic illnesses have worse outcomes than the general population. Antipsychotic 
medications are effective at addressing the symptoms of illness, but have little to no success at 
addressing many of the associated problems of the illnessThere has undoubtedly been many 
benefits of their use in the control of symptoms, particularly positive symptoms of psychotic illness, 
and the reduction of relapse rates 1. Despite this, and even with the introduction of second-
generation antipsychotic medication there has been little indication that people with psychotic 
illness have returned to functional roles in any great number. For example, people diagnosed with 
psychotic illnesses 2 are less likely to complete their secondary education3 and unemployment 
remains a highly prevalent problem associated with the disorder. Loneliness is also a significant issue 
for young people with psychosis, so much so that the onset of psychosis has been characterised as a 
social network crisis which is not ameliorated by current interventions4. In a range of other 
functional domains, housing security,5 physical health6, social relationships and engagement in 
community7, people with psychotic illnesses have worse outcomes than the general population. 
Antipsychotic medications are effective at addressing the symptoms of illness but have little to no 
success at addressing many of the associated problems of the illness(Alvarez-Jimenez et al., 2016)8.  
Yet, it is these problems that people living with psychosis most want most addressed(Ramsay et al., 
2011)9.  
Data from studiespapers published over the last 511 years(Wunderink, Nieboer, Wiersma, Sytema, & 
Nienhuis, 2013; Wunderink et al., 2007)10,11 have raised the question of how the best balance or 
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“sweet-spot” is struck between exposure to antipsychotic medication, symptomatic improvement, 
the minimisation of iatrogenic harm and maximising functional recovery(Correll, Rubio, & Kane, 
2018).12. The study described in this paper seeks to answer this question. 
Background 
After remission from acute symptoms of psychosis is achieved,  most treatments for psychosis have 
focussed upon the prevention of psychotic relapse (N. Andreasen et al., 2005; Program, 2016). 
Relapse prevention is a worthy clinical goal, due to the potential for distress and other risks 
associated with acute symptoms,  the direct cost of multiple hospital visits associated with 
relapse(Knapp et al., 2013), as well as relapsing courses of psychosis being up to 4 times more 
expensive than non-relapsing courses (Almond, Knapp, Francois, Toumi, & Brugha, 2004; Ascher-Svanum et al., 2010). Less focus 
has been placed on improving social and vocational functioning despite these being the primary 
goals of people who experience psychosisAfter remission from acute symptoms of psychosis is 
achieved,  most treatments for psychosis have focussed upon the prevention of psychotic relapse 
13,14. Relapse prevention is a worthy clinical goal, due to the potential for distress and other risks 
associated with acute symptoms,  the direct cost of multiple hospital visits associated with relapse15, 
as well as relapsing courses of psychosis being up to 4 times more expensive than non-relapsing 
courses 16,17. Less focus has been placed on improving social and vocational functioning despite these 
being the primary goals of people who experience psychosis(Iyer, Mangala, Anitha, Thara, & Malla, 2011; Ramsay et al., 
2011)9,18. For this reason, as well as being the cause of 50% of the total illness costs, functional 
recovery of people with psychotic illness warrants further attention(Alvarez-Jimenez et al., 2016)..  
In this context we define functional recovery to mean- age appropriate vocational functioning, 
having social outlets, such as friends beyond onesone’s immediate family and participation in 
onesone’s community through such activities as voting.  
The impact of antipsychotic maintenance treatment  
Current evidence based treatment guidelines recommend antipsychotic maintenance treatment for 
2-5 years after a First Episode of Psychosis (FEP) (Program, 2016), followed by annual 
review(Program, 2016). In reality, maintenance treatment can continue for decades(N. C. Andreasen, Liu, 
Ziebell, Vora, & Ho, 2013), partly due to the lack of clarity and evidence around how long individuals should 
receive antipsychotic treatment(Program, 2016; Sohler et al., 2016).   The goal of current guidelines 
is to prevent symptomatic relapse rates in FEP clientsCurrent evidence based treatment guidelines 
recommend antipsychotic maintenance treatment for 2-5 years after a First Episode of Psychosis 
(FEP) 13, followed by annual review13. In reality, maintenance treatment can continue for decades19, 
partly due to the lack of clarity and evidence around how long individuals should receive 
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antipsychotic treatment13,20.   The goal of current guidelines is to prevent symptomatic relapse rates 
in FEP clients(Chen et al., 2010; Emsley, Chiliza, & Asmal, 2013)21,22. Arguments in favour of ongoing maintenance 
treatment are that: in the absence of medication, risk of  relapse rises significantly, episodes of 
relapse tend to become longer after the initial episode(Emsley, Chiliza, & Asmal, 2013)22; response to 
medication takes longer; and approximately 14% at each relapse will not respond to 
medication(Emsley, Chiliza, Asmal, & Harvey, 2013).  While maintenance treatment is generally 
successful at treating positive psychotic symptoms(Sohler et al., 2016), the associated side-effects of 
antipsychotic medication can be a case of significant harm. These side-effects include weight gain 
(Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004; Klemp et al., 2011), sexual dysfunction(Program, 2016) and possible 
contribution to poor functional recovery in (Wunderink et al., 2013)people with positive symptom remission.  
These associated side-effects can result in poor medication adherence(Coldham, Addington, & 
Addington, 2002). In fact adherence to antipsychotic medication is poor in FEP; around 60% of them 
have either non adherence or poor adherence. Further implications of maintenance treatment 
include metabolic disturbances which lead to increased risks for cardiovascular disease and 
diabetes(De Hert et al., 2011). One consequence of this is the 20-30 year reduction in life expectancy in 
people with psychosis (Olfson, Gerhard, Huang, Crystal, & Stroup, 2015; Subotnik, Nuechterlein, Ventura, & Marder, 2011). Metabolic 
and cardiovascular illness, in large part due to antipsychotic medication(De Hert et al., 2011), accounts for 
the majority of this mortality. (Hage et al., 2018) 
 
; response to medication takes longer; and approximately 14% at each relapse will not respond to 
medication23.  While maintenance treatment is generally successful at treating positive psychotic 
symptoms20, the associated side-effects of antipsychotic medication can be a case of significant 
harm. These side-effects include weight gain 24,25, sexual dysfunction13 and possible contribution to 
poor functional recovery in 10people with positive symptom remission.  These associated side-effects 
can result in poor medication adherence26.Adherence to antipsychotic medication is poor in FEP; 
around 60% of them have either non adherence or poor adherence27. Further implications of 
maintenance treatment include metabolic disturbances which lead to increased risks for 
cardiovascular disease and diabetes and the potential for a  20-30 year reduction in life expectancy 
in people with psychosis28,29,30. Metabolic and cardiovascular illness, in large part due to 
antipsychotic medication28, accounts for the majority of this mortality. 31 
 
In addition, maintenance treatment studies(Waghorn et al., 2012)3 and meta-analyses(Alvarez-
Jimenez, Parker, Hetrick, McGorry, & Gleeson, 2011)32 over the last 10 years have found a 
relationship between exposure to antipsychotic medication and changes in brain volume. Recent 
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cross-sectional evidence indicates that antipsychotic medications may produce reductions in grey 
and white matter volumes(Alvarez-Jimenez et al., 2011)32 (Bola & Mosher, 2002).33.  One study in 
particular found medicated FEP patients to display significant cortical thinning in the dorsolateral 
prefrontal and temporal cortices when compared to unmedicated FEP patients, who had cortical 
thickness measures similar to controls(Lesh et al., 2015).34. Moreover, a 7-year longitudinal 
neuroimaging study in FEP showed that loss of brain tissue occurs at the rate of 0.56cc56 cubic 
centimetres in patients receiving an average of 4mg/day of haloperidol (dose equivalent) over a 1- 
year period(N. C. Andreasen et al., 2013).19. Intensity in dose years of antipsychotic treatment was 
associated with reductions in total cerebral volume as well as frontal lobe and white matter 
volumes. However, without a control group this study could not establish whether brain volume 
reductions are a direct consequence of maintenance treatment or rather are accounted for by other 
illness-related factors. Given that early psychosis is associated with significant loss of grey matter 
volume over time relative to healthy controls(Bowie, McLaughlin, Carrion, Auther, & Cornblatt, 
2012)35 , there is a possibility that medication discontinuation could reduce this loss, or preserve 
brain changes such that they are comparable to neurotypical same-age peers. Further, some 
evidence suggests that antipsychotic treatment may alter cerebral function in FEP(Lesh et al., 2015; 
Lui et al., 2010) (Radua et al., 2012; Sarpal et al., 2015) and the impact of a dose reduction strategy 
on functional connectivity of resting-state neural networks is currently unknown. 34,36-38. Additionally, 
cognitive function may be adversely affected by maintenance treatment. Evidence for this comes 
from threeThree naturalistic studies in prodromal and established schizophrenia groups 
showingshow a relationship between level of exposure to antipsychotic medication and decline in 
cognitive function over time(Faber, Smid, Van Gool, Wiersma, & Van Den Bosch, 2012; Husa et al., 
2014; Weickert et al., 2013)39-41. As symptom intensity or persistence may confound this 
relationship. Furthermore, meta-analytic evidence suggests that the processing speed impairment 
observed in psychotic disorders is significantly associated with chlorpromazine equivalent daily 
dose.42 As symptom intensity or persistence may confound the relationship between cognitive 
performance and antipsychotic dose, randomised controlled trials are required.  
A recent small (N=53) guided anti-psychotic discontinuation RCT in FEP found that cognitive function 
improved in remitted FEP clients who received guided discontinuation compared with those who 
received maintenance treatment over a five month follow up period(Faber et al., 2012). These 
differences may be explained by the fact that antipsychotic dopamine blockade can lead to impaired 
verbal learning in psychosis(Weickert et al., 2013).  If the positive impact of maintenance/reduced 
antipsychotic treatment combined with psychosocial treatment on the brain’s structure can be 
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confirmed, we will investigate whether attenuation of brain volume reductions acts as a 
mediator/moderator of psychosocial functioning (Bola & Mosher, 2002; Patrick McGorry, 2005).  
This is in line with previous research that has also shown that adherence to high/standard-dose 
maintenance treatment is associated with poorer psychosocial functioning early in the course of 
recovery, suggesting that a strong focus on high-dose maintenance medication may interfere with 
long-term recovery (Wunderink et al., 2013). This is also consistent with the follow-up results from the 
Episode II trial(J. F. Gleeson et al., 2009).  
Although maintenance treatments for psychotic illnesses significantly reduce relapse rates compared  
with placebo, they do not achieve the functional goals of people who experience psychosis.   
Two small double-blind placebo-controlled crossover studies of inpatients with schizophrenia (N=27 
and N=19, respectively) found that antipsychotic medication was associated improved cognitive 
performance compared with placebo43,44. A recent guided anti-psychotic discontinuation RCT in FEP 
(N=53) found that cognitive function improved in remitted FEP clients who received guided 
discontinuation compared with those who received maintenance treatment over a five month follow 
up period40. Previous research has also shown that adherence to high/standard-dose maintenance 
treatment is associated with poorer psychosocial functioning early in the course of recovery, 
suggesting that a strong focus on high-dose maintenance medication may interfere with long-term 
recovery 10. This is also consistent with the follow-up results from the Episode II trial45.  
A recent critical review also proposed that although anti-psychotic maintenance may be efficacious 
in mid-term treatment of psychosis, there is a paucity of evidence supporting the efficacy of this 
treatment approach in the long-term, this supports further investigation of a dose reduction 
strategy12.  
 
Is dose reduction the answer?  
The negative impacts of long -term maintenance have raised the question of whether dose reduction 
might be associated with better outcomes for individuals affected by psychotic disorders. Recent 
evidence showing that functioning improves with a strategy to reduce the dose of antipsychotic 
medication suggests that functional recovery may be suppressed by long-term exposure to 
antipsychotic medication(P. D. McGorry, Alvarez-Jimenez, & Killackey, 2013; Wunderink et al., 2013).10,46. A meta-analysis of 
RCTs of antipsychotic treatments in FEP clients showed that approximately 40% of placebo-treated 
FEP clients had not relapsed at 1-year follow up(Alvarez-Jimenez et al., 2011).32. Subsequently, one recent RCT 
revealed that, when compared with continuous maintenance treatment, the discontinuation of 
maintenance treatment in FEP led to improved recovery at 7 years follow up(Wunderink et al., 
2013).10. Importantly, this occurred in the absence of intensive psychosocial treatments that may 
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hasten improvement of functioning and prevent relapse(Alvarez-Jimenez et al., 2011).32. Thus, recovery may be 
enhanced or hastened if a dose reduction strategy were combined with intensive evidence based 
psychosocial interventions. These findings suggest that, despite current guidelines, FEP clients may 
not require maintenance treatment for the initial recommended two-year minimum period to attain 
recovery and prevent relapse. Indeed, previous research has shown that it is early functional 
recovery rather than symptomatic recovery that predicts functional recovery at 7.5 years (Alvarez-Jimenez 
et al., 2012).47. 
Arguably, patient non-adherence(Gitlin et al., 2001),48, and planned discontinuation of maintenance 
treatment both pose risks for relapse after FEP(Alvarez-Jimenez et al., 2012).47. However, as reduction in 
symptoms dodoes not automatically translate into functional gains. Prioritising relapse prevention 
without also giving full consideration to the implications for functional recovery may compromise 
the long-term outcomes most valued by those who experience the illness (PD. McGorry, 2007; Ramsay et al., 2011) 
.9,49 .  
Management of relapse risk therefore, should be balanced with a focus on functional recovery and 
the costs of long-term continuous maintenance treatment, including probable enhancement in 
functioning(Alvarez-Jimenez et al., 2011).32. A promising balanced approach to treatment includes a dose 
reduction strategy, combined with intensive and recovery-focussed psychosocial treatments with 
vigilant monitoring for early signs of relapse(Carpenter, Appelbaum, & Levine, 2003).50.  
Supplementary to a dose reduction strategy, the use of an evidence-based intensive recovery 
treatment (EBIRT) should be employed to improve likelihood of overall functional outcomes. In the 
present study, EBIRT combines two previously trialled interventions. These interventions are 
Individual Placement and Support (IPS) for vocational recovery and CBT for Relapse Prevention. IPS 
in addition to specialist FEP treatment has produced significantly better outcomes in gaining 
employment, hours worked, jobs acquired, and longevity of jobs compared to specialist FEP 
treatment alone (J. F. Gleeson et al., 2009; E. Killackey, Jackson, & McGorry, 2008).45,51.  CBT for relapse prevention 
combined with specialist FEP treatment when compared with specialist FEP treatment alone(J. F. Gleeson 
et al., 2009),45, led to a significant reduction in relapse rates at 7-months follow up in FEP clients who 
met remission on positive symptoms. This effect was sustained at 1 year, and relapse rates were 
kept to historically low levels beyond this time point (30% at 2.5 years) (J. F. Gleeson et al., 2009; J. F. M. Gleeson et 
al., 2013).45,52. However, these differences were no longer significant at 30 -month follow-up.  
Importantly, 83% of clinicians providing care to people experiencing (Thompson, Singh, & 
Birchwood, 2016)Importantly, 83% of clinicians providing care to people experiencing FEP would 
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support a carefully monitored dose reduction strategy after patient relapse, and believe this would 
improve the quality of life of their clients.53. This further supports the acceptability of a dose 
reduction strategy, particularly in a FEP setting48,(National Collaborating Centre for Mental Health, 
2014; ORYGEN Youth Health, 2010)54,55 
 
Aims 
The primary aim of the study is to compare functional outcomes between a dose reduction strategy 
with EBIRT group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at 
24-months follow up.  
This study has a range of secondary aims:  
1. To compare physical health and metabolic profiles between DRS+ and AMTx+ at 24-months 
follow up. 
2. To compare grey and white matter volume between DRS+ and AMTx+ at 24-months follow 
up. 
3. To compare brain activity during resting-state between DRS+ and AMTx+ at 24 months 
follow up.  *. 
4. To compare cognitive functioning between DRS+ and AMTx+ at 24-months follow up. 
5. To compare remission and relapse rates between DRS+ and AMTx+ at 24-months follow up. 
 
*This is a largely exploratory aim, however based on the limited literature in this area we hypothesis 
that the DRS+ group would display greater resting state functional connectivity than the AMTx+ and 
healthy control groups 
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Primary hypothesis 
H1: Remitted FEP patients randomised to DRS+ will achieve superior social and vocational 
functioning at 24-months follow up, compared with remitted FEP patients randomised to AMTx+. 
Secondary hypotheses 
H2: Participants randomised to DRS+ will have less reduction in grey and white matter volume than 
participants randomised to AMTx+ at 24-months follow up.  
H3: Degree of antipsychotic exposure will be negatively associated with grey and white matter 
volume at 24-months follow up. Further, it is expected that change in neural activity during resting 
state will differ significantly between the DRS+ and AMTx+ groups at 24-months follow-up.  
H4: Participants randomised to DRS+ will have better cognitive functioning compared to participants 
randomised to AMTx+ at 24-months follow up.  
H5: Participants in the AMTx group will have experienced fewer relapses at 24-months follow up.  
H6: Participants randomised to DRS+ will have significantly better metabolic indices (defined as 
being within normal parameters) and an improved physical health status at 24-months follow up. 
 
Ethical approval 
This study was approved by the Melbourne Health Human Research Ethics Committee 
(HREC/16/MH/309) in February 2017 and began recruiting participants in July 2017.  The trial is 
registered on the Australian and New Zealand Clinical Trials Registry (12617000870358).  
 
Methodology 
Study Design 
This study is a single blinded non-placebo randomised controlled trial where research assistants are 
blinded to treatment allocation.  
Study Setting 
This study will be conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC), a 
sub-program of Orygen Youth Health (OYH). OYH is a youth public mental health service in 
Melbourne for 15 to 25-year-olds (inclusive). EPPIC is a comprehensive specialist early psychosis 
program that provides outpatient case management and psychiatric treatment., psychosocial 
intervention and psychiatric treatment. OYH is co-located with Orygen, the National Centre of 
Excellence in Youth Mental Health and the Centre for Youth Mental Health, The University of 
Formatted: Font: 12 pt
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Melbourne. EPPIC provides up to 2 years of specialised care after which clients are transferred to 
another service depending upon the level of care required. A proportion of clients receive follow-up 
care within primary care settings, while others may continue to require case-management and 
specialist care and are therefore transferred to the adult mental health service.  The Reduce Trial will 
embed specific resources within EPPIC, including a proportion of one psychiatry registrar position, a 
Vocational Support Worker and a number of specialist Reduce trial case managers, who will provide 
the medical oversight, the vocational recovery support and the clinical case management for trial 
participants, respectively.   
Inclusion and Exclusion Criteria  
Inclusion and Exclusion Criteria have been designed to reflect ‘real-world’ characteristics of young 
people presenting to clinical settings with a FEP.  
Inclusion Criteria: (i) Current client of EPPIC; (ii) A confirmed diagnosis of first episode of a DSM 
5(Association, 2013)56 psychotic disorder or mood disorder with psychotic features(Association, 
2013; First MB, 2015);56,57; (iii) Aged 15-25 years (inclusive); (iv) ≥ 3 months of remission on positive 
symptoms of psychosis in the first year of antipsychotic treatment (participants must currently be 
taking their prescribed anti-psychotic medication) at EPPIC (a score of  ≤3 (mild) on the 
hallucinations, unusual thought disorder, conceptual disorganisation, and suspiciousness subscale 
items of the Brief Psychiatric Rating Scale (BPRS)(Ventura et al., 1993)58 for the past two weeks and a 
score ≤3 on the hallucinations, unusual thought content, conceptual disorganisation, and 
suspiciousness subscales of the BRPS(Ventura et al., 1993)58 for the past 3 months based on a 
systematic clinical file review and collateral information collected from the part cipant’s treating 
team in EPPIC (as needed); (v) Low suicidality defined as a score of 4 or below on the BPRS(Ventura 
et al., 1993)58 sustained for the past 1-month period prior to baseline; (vi) The young person is 
willing for a caregiver to be informed about the study and will have at least weekly contact with their 
caregiver; (vii) Ability to provide written informed consent. 
Exclusion Criteria: (i) A documented history of an intellectual disability or IQ <70; (ii) Inability to 
converse in or read English; (iii) Women who are currently pregnant or breastfeeding; (iv) 
Neurological disorder. (illness of the brain, nerves or spinal cord which could not better explain the 
presence of psychosis).  
Recruitment, Consent, and Enrolment and Randomisation  
Participants will be recruited into the trial through a number of strategies- including regular case 
review discussions between the Reduce research assistant (RA) and EPPIC Consultants, direct 
Page 13 of 65 Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Dose reduction in FEP: Study Protocol  
 
13 
 
referral to Reduce from EPPIC Clinicians and through the RA attending regular EPPIC team meetings 
to discuss ongoing eligibility of clients nearing three months of psychotic remission. Potential 
participants are then approached to take part in the trial by either the RA, Reduce registrar or case 
manager. They are given ample time to consider the option to take part in Reduce and are 
encouraged to discuss this with their family, local doctor and other supports. Before being enrolled 
in the study all participants will provide written and informed consent. In the case of minors, their 
parent or legal guardian will also be required to provide written and informed consent. After the 
consent process is complete, a Core Baseline assessment is administered by the research assistant. 
Eligibility is assessed, using the BPRS(Ventura et al., 1993)58 and the SCID-RV(First MB, 2015). 
Participant clinical notes will also be used for collateral information to confirm eligibility. If eligibility 
is confirmed from the above assessments, participants will be randomised to either AMTx+ or DRS+ 
at a ratio of 1:1 and randomisation will be stratified by sex assigned57. Participant medical files and 
EPPIC clinical files will also be used for collateral information to confirm eligibility  
Method of Assigning participants to Treatment Groups and Randomisation 
An independent statistician will organise the randomisation. The randomisation will be stratified by 
sex at birth (male vs. female) and baseline diagnosis (affective vs. non-affective) as these 
characteristics are associated with key outcomes in this study and any chance imbalances may bias 
the analysis. Following randomisation, the Non-Core Baseline Assessment will be completed within 3 
weeks.Participants will be allocated to either the EBIRT (AMTx+) or EBIRT (DRS) treatment groups 
using randomly permuted blocks of varying size within each stratum, to maintain approximately 
equal group sizes over time. The randomisation sequences will be concealed within a secured 
password protected website. On obtaining informed consent of a new participant, the delegated 
research team member will access this website and enter the participant’s details. The delegated 
research team member will then inform the treating team the randomisation outcomes who will 
then inform and discuss this with the participant.   
A client identification (ID) number will be allocated to clients approached to ascertain their eligibility 
to participate in the study. Each eligible participant will be allocated to a unique and sequential 
randomization number. 
Healthy Control Group 
Because the age range of participants covers a time of significant neurodevelopment, 40 healthy 
controls aged 15-25 years (inclusive), living in the EPPIC catchment, with no history of mental illness, 
neurological condition or antipsychotic medication treatment will also be recruited. They will 
undergo MRI scanning, be cognitively assessed and have physical health indicators measured (except 
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bloods) at the same four time points as the DRS+ and AMTx+ groups (baseline, 9-months, 15-months 
and 24-months). This will provide objective control data to determine whether there are physical 
health, brain volume and neural activation or cognition changes and if they are related to illness, 
medication or typical development. 
Outcome Measures 
The primary outcome measure is the Social and Occupational Functioning Scale(Goldman, Skodol, & 
Lave, 1992) (SOFAS) at 24 -months.59 (SOFAS) at 24 -months. In addition to the primary outcome 
measure, a number of measures will assess physical health and metabolic profiles, brain 
volumes/activity, cognitive functioning and remission and relapse rates at 24-months.  
Secondary Endpoint measures 
Symptomatology 
Remission and relapse of positive symptoms will be assessed using the expanded Brief Psychiatric 
Rating Scale(Overall & Gorham, 1962) (BPRS) in treatment groups only. Remission of negative 
symptoms will be assessed using the Scale for Assessment of Negative Symptoms (SANS)(N.C. 
Andreasen, 1984).  
Neurocognitive assessments 
A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia(Keefe 
et al., 2008)Remission and relapse of positive symptoms will be assessed using the expanded Brief 
Psychiatric Rating Scale60 (BPRS) in treatment groups only. Remission of negative symptoms will be 
assessed using the Scale for Assessment of Negative Symptoms (SANS)61. The a priori clinically 
significant degree of difference on duration of relapse is 7 days, in accordance with published 
duration criteria52.  
Neurocognitive assessments 
A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia62 
(BACS App) will be used to assess cognitive functioning in all groups, including healthy controls. 
Further detail of the full neurocognitive battery can be found in the Schedule of Assessments (Table 
1).  
 
INSERT TABLE 1 ABOUT HERE 
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Physical health assessments 
Blood pressure, weight, height and waist circumference will also be recorded in all groups including 
healthy controls.  
Haematological investigations 
Physical health will be measured by clinical blood analysis evaluating fasting glucose, haemoglobin 
A1C, triglycerides and lipid levelsTotal HL cholesterol in the treatment groups only. 
Brain imaging 
Brain volume will be quantified in both treatment groups and healthy controls by high-resolution 
magnetic resonance imaging (MRI).  In addition to structural MRI, functional resting state data will 
also be collected.  
Study Intervention  
Intervention 
After randomisation and allocation to one of the two conditions, all participants will commence the 
intensive EBIRT phase in which they will attend up to twice weekly individual therapy and vocational 
support sessions until Month 9.  
Evidence-Based Intensive Recovery Treatment (EBIRT)  
EBIRT combines two well-validated and manualised psychosocial interventions: Individual Placement 
and Support (IPS) for vocational recovery and Cognitive Behaviour Therapy (CBT) for Relapse 
Prevention. EBIRT will be delivered in two phases; a 9-month intensive phase which entails up to two 
sessions of individual therapy (one CBT sessions and one IPS session) per week for 9-months,. All 
participants will receive 9 months of the EBIRT intensive phase. This will followed by a 6-9 month 
(dependent on tenure remaining in service)-) - maintenance/monitoring phase in which individual 
therapy sessions will be delivered every 4-6 weeks.  
 The first component of EBIRT is CBT. This will be provided by a therapist trained in CBT and is 
comprised of six or more modules of therapy delivered over the 9 -month intensive period. The six 
phases of EBIRT intervention include: (1) initiation of vocational intervention (2) formulation and 
agenda setting; including vocational goal setting; (3) engagement and assessment for recovery and 
risk for relapse; (4) psychoeducation with a focus on relapse; (5) early warning signs and relapse 
planning – will also involve family members with participant’s consent; and, treatment and progress 
review (6). Additional optional modules may be drawn upon depending on case formulation and 
clinical determination in collaboration with the participant include: substance abuse, stress 
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management, and co-morbid anxiety and depression at the investigator’sparticipant or clinician 
discretion.  The second component of EBIRT is IPS. This will focus on (a) focussed upon competitive 
employment, education or training as an outcome; and (b) focussed upon immediate job/education 
searching and will be delivered by a Youth Specialist Vocational Consultant.  In tandem with EBIRT, 
participants will be randomly assigned following baseline assessment to either the DRS+ or AMTx 
treatment conditions.  
DRS will comprise a 9-month EBIRT phase (DRS+). The comparator group will receive AMTx and 
EBIRT (AMTx+). The EBIRT intervention will be the same in both groups. The AMTx group treatment, 
including medication prescription will be in accordance with published treatment guidelines. The 
Reduce trial clinicians will collect data on frequency, content and duration of therapy sessions in 
order to measure treatment compliance for the duration of the 15-18 month EBIRT treatment.  
 
At Month 9, all participants will transition into the lower intensity monitoring phase of EBIRT in 
which they will attend individual therapy sessions with their Reduce case manager every 4-6 weeks 
for a minimum of 6 months. All participants will receive a minimum ofat least 15 months of EBIRT 
therapy however they may receive up to total Reduce treatment and a maximum of 18 months, 
depending on the balance ofhow long their time left inpsychotic symptoms take to stabilise upon 
entry into EPPIC. AllThis means that some participants will be entitled to receive a total of 24- 
months of EPPIC treatment whereby, some participants will receive 27 months total EPPIC 
treatment. Participants are entitled to the full EPPIC treatment package throughout this time and 
can have the frequency of appointments with EPPIC team increased should there be a clinical 
indication to do so.  Differences in EPPIC treatment will be recorded. 
Dose Reduction Strategy (DRS+) group 
Participants who are randomised to this arm of the trial will be offered a gradual dose reduction of 
their antipsychotic medication. at their next medical review after randomisation. Medication will be 
tapered under close medical supervision over 3-months after allocation to the DRS group to 
minimise the risk of relapse due to abrupt discontinuation. The rate of tapering will be a 25% dose 
reduction (or as near to 25% as the medication allows) of the pre-reduction dose every month for 3 
months, if clinically safe as determined by the EPPIC treating team.until the participant reduces a 
dose that is considered clinically safe, whereby some participants will completely cease taking the 
antipsychotic medication. This will see some variation in participants’ reduction schedule. All data on 
the rate of dose reduction will be collected by the Reduce clinicians to measure the variations in 
participant treatment.  Formatted: Font: 11 pt
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Antipsychotic Maintenance Treatment (AMTx) group 
Participants will be prescribed medication as clinically indicated, concordant with the Australian 
Clinical Practice Guidelines for FEP(National Collaborating Centre for Mental Health, 2014; ORYGEN 
Youth Health, 2010).54,55. These guidelines recommend the use of the lowest effective dose of 
atypical antipsychotics.  
All trial participants will have access to all components of treatment at EPPIC, including psychiatric 
care, case management, psychosocial program, acute inpatient care and outreach as clinically 
indicated.(N.C. Andreasen, 1984; Keefe et al., 2008; Ventura et al., 1993)58,61,62 
Safety Measures 
Participants will be managed within the EPPIC clinic at OYH. Participants will be monitored by the 
treating team. Clinical appointments can be held more frequently when clinically indicated.  In 
addition, the BPRS(Ventura et al., 1993)58 and SOFAS(Goldman et al., 1992)59 scales will administered 
weekly by the participant’s EBIRT Clinician to assess for participant symptomatic relapse, and to 
measure the acceptability and safety of the prescribed dose. The SOFAS will measure functioning 
during the 9-month intensive phase. SafetyThese safety assessments will thencontinue to occur 
every 4-6 weeks up until Month 24 and administered by either the EBIRT Clinician or the Research 
Assistant.  
Relapse and Temporary Pause or Complete Discontinuation from DRS+ 
In the event of symptomatic relapse or worsening of symptoms, and the participant meeting the 
criteria for relapse described in Table 2, the participant’s dose reduction treatment may be 
temporarily paused.  
Table 2 presents the criteria used to define psychotic relapse and will result in a temporary pause 
from the DRS+ treatment. These relapse criteria have been developed with the aim of reflecting 
‘real-world’ relapse of FEP.  Participants must satisfy either Criteria 1, 2 or 3 in combination with 4 to 
meet relapse criteria.(Ventura et al., 1993)58 There is also a ‘fail-safe’ option should stopping the DRS 
be clinically indicated.  
*TABLE 2 HERE* 
If the above criteria are not met but the participant is considered by their treating clinical team to 
have significantly deteriorated in relation to psychotic symptoms compared to baseline, and clinical 
response is deemed necessary, they may also be temporarily paused from the DRS+. Participants will 
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be monitored by their treating team and study personnel and regularly assessed for relapse, 
psychotic exacerbations and functioning.  
In the event of a temporary pause in the dose reduction strategy the clinical team will make a 
decision as todecide whether the participant should restart their antipsychotic medication or 
increase their dose. Any changes made will be in consultation with the participant.  
If antipsychotic medication is recommenced or if the dose is increased, it will be titrated up until an 
effective dose is reached. Titration will occur at a pace appropriate to the individual's clinical 
presentation and should allow adequate time for a response at each dosing interval. In this case, 
psychiatry registrars will discuss appropriate dose with treating consultants and ensure any changes 
are documented. If the participant fails to achieve satisfactory recovery defined by persistence of 
severe psychotic symptoms whilst consistently meeting criteria described in Table 2 for 3 months 
following the initial relapse, or if they become pregnant during the study they will be completely 
discontinued from DRS+, whilst still remaining in EPPIC and receiving EBIRT. These participants will 
also be invited to continue with the research assessments and included in intention-to-treat 
analyses.  
Table 3 outlines the study schema 
*TABLE 3 HERE*  
Participants discontinued from the AMTx+ group will continue to receive treatment in accordance 
with the Australian Clinical Practice Guidelines and may choose not to participate in EBIRT. . If they 
wish they may continue with EBIRT and the research assessments. These participants will also be 
included in intention-to-treat analyses. 
Withdrawal Criteria 
A participant will be withdrawn from the study if they choose to no longer participate in the Reduce 
study voluntarily, fail to achieve satisfactory recovery defined by persistence of severe psychotic 
symptoms whilst consistently meeting criteria described in Table 2 for 3 months following the initial 
relapse, or if they become pregnant during the study. A participant will be considered ‘withdrawn’ 
from the study in cases where all involvement in the trial is ceased. and no further follow up is 
enacted 
Blinding  
The delegated study statistician will be blind to treatment allocation. Research assistants (RAs) will 
also be blind to treatment allocation. The study RAs will be kept blind to treatment allocation using 
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the following processes: (a) regular reminders will be sent to clinical staff at EPPIC, regarding the 
importance of the blind; (b) at the start of each research interview the RA will remind the 
participants of the importance of the blind; (c) the RA will have restricted access to participants’ 
medical records. The unblinded Project Manager will have access to the participant’s medical 
records and will retrieve and provide study RA’s with any information that is required (i.e. for 
screening). Because the extent and rate of dose tapering in each individual case requires clinical 
tailoring in response to preceding dose reductions, it is not feasible to utilise a placebo control, so 
medication treatment will be open-label, with medications chosen by EPPIC psychiatrists. 
Statistical methods and determination of sample size 
Data analysis will be conducted at the completion of the study (24-months from last patient first 
visit) and as such there will be no interim analyses conducted. The primary outcome is SOFAS score 
at two-year follow-up. Calculations of effect size are based on detecting a two-year follow-up effect 
size of d=0.505, based on our previous relapse prevention studies which found a group difference of 
this magnitude on the SOFAS at two-year follow-up. Power is set at 0.85, α = .05 (two-tailed). The 
estimated sample size is 144 (n=72 per group). To accommodate an attrition rate of 20%, the target 
sample size will be 180, or 90 participants per treatment group. Differences on social and vocational 
functioning measures will be examined using mixed model repeated measures and intention-to-treat 
analysis, which are preferred methods for the analysis of clinical trial data in psychiatry. The a priori 
clinically significant degree of difference on duration of relapse is 7 days, in accordance with 
published duration criteria(J. F. M. Gleeson et al., 2013).. Between-group differences on vocational 
status will be examined using logistic regression. Patterns of missing data and missing data 
mechanisms will be investigated using two approaches; firstly, Little’s missing completely at random 
(MCAR) test will be used to assess the degree to which the data are likely to meet the MCAR 
mechanism; secondly, prediction of missingness at each of the assessment points will be undertaken 
using binary logistic regression, with a range of baseline sociodemographic, clinical, and 
psychopathology variables used to predict the presence or absence of a particular assessment.  
Likelihood techniques will be used to address missing data. The same statistical models described 
above will be used to characterise the effects of treatment regimen on grey and white matter 
volumes. Flexible factorial models will be used to estimate significant within-and between-group 
activation effects at the whole brain level (using F-tests) to determine the effects of treatment 
regimen on brain function. A cluster-based permutation approach will be used to identify significant 
differences satisfying a Family Wise Error rate of .05. Age and sex assigned at birth will be controlled 
for in all analyses. 
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Data Safety Monitoring Board  
A Data Safety Monitoring Board will be established in accordance with ICH-GCP Guidelines and the 
NHMRC’s 2018 guidelines on DSMBs.  
Trial Status  
The study commenced enrolling participants in July 2017. Enrolment is continuing at the time of 
manuscript submission. The report of the study findings is expected in 2024.  
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Table 1  
Outline of Schedule of Assessments  
 
Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Informed Consent4 X      
Inclusion/Exclusion Criteria X      
Demographics X  X X  X 
Medical & Psychiatric History  X     
Pregnancy (urine)5 X   X  X 
 
1  Core Baseline assessments may be conducted over a number of visits to allow for ‘real-world’ scenarios however, must be completed prior to 
randomisation.  
2  Non-Core Component Baseline assessments may be conducted over a number of visits to allow for ‘real-world’ scenarios and can be completed up to 3 
weeks after randomisation.  
3  Telephone contact every 6 weeks from Month 9-24 to check discontinuation/withdrawal criteria.  
4  Informed consent can be obtained up to 21 days prior to baseline.  
5  In addition to conducting urine pregnancy tests at each baseline and 24-month assessments, participants will also be asked to indicate whether they are 
pregnant or not during 9-month, 15-month assessments and telephone follow-ups. 
Page 30 of 65Early Intervention Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Dose reduction in FEP: Study Protocol  
 
30 
 
 
Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Concomitant Med. Review6  X X X X X 
Treatment Allocation       
Randomisation X      
Diagnosis       
SCID5-RV (Modules A & B)  X   X  X 
Intervention       
Participants in DRS+7       
EBIRT8         Post intervention Follow up  
 
6  To maintain blinding of RAs, EBIRT clinicians will review medication adherence weekly (every second session) during the EBIRT intensive phase and 
every session during the EBIRT maintenance phase. EBIRT clinicians will also check concomitant medications every 6 weeks during the intervention phase 
(up to minimum of 15 months).  
7  Reduce antipsychotic medication dose by 25% every month for 3 months as clinically indicated. 
8  EBIRT intensive phase: Twice weekly individual therapy sessions to month 9, maintenance/monitoring phase 4-6 weeks individual therapy for a 
minimum of 6 months. A checklist recording details and items covered in of the EBIRT (CBT) Session will be completed every session by the Clinician and 
entered directly into the eCRF. The IPS Worker will also complete a checklist recording items covered in every session and enter this in to the eCRF. This 
data will be used to assess fidelity of EBIRT.   
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Medication Compliance       
Clinician’s compliance rating5  X X X   
MARS5  X X X  X 
Medication side effects       
LUNSERS  X X X  X 
Symptomatology       
BPRS9 X  X X X X 
SANS  X X X  X 
DASS-21  X X X X X 
CDSS  X X X  X 
IPASE  X X X  X 
Functioning & Quality of Life       
SOFAS8  X X X X X 
Vocational functioning  X X X X X 
 
9  In addition to assessment time-points and telephone follow-up, the BPRS and SOFAS will be measured weekly during the intensive phase and at therapy 
sessions during the maintenance phase for purposes of discontinuation criteria.   
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
WHOQoL-BREF  X X X  X 
ULCALS  X X X  X 
MHCS  X X X  X 
The Self-efficacy Scale  X X X  X 
BPNS   X X X  X 
Daily functioning and affect       
SEMA10  X X X  X 
Pre-morbidity and Illness       
NOS  X     
Trauma       
CTQ  X     
Metabolic monitoring       
Clinical Bloods11  X X X  X 
 
10  SEMA will be used to deliver electronic surveys (to be administered directly after the baseline and follow up assessments (visits 1-4) at 8 time 
points per day in the waking hours of each participant for a period of 7 days. Only participants who have smartphones will complete these surveys.  
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Blood pressure, height, weight and 
waist circumference12 
 X X X  X 
Substance Use       
AUDIT  X X X  X 
 ASSIST   X X X  X 
Neurocognitive       
WRAT-4  X     
BACS  X X X  X 
ER-40  X X X  X 
The Hinting Task  X X X  X 
                                                                                                                                                                                                                                                                                      
11  Clinical bloods will involve testing for fasting glucose, haemoglobin A1C, and lipid levels (fasting triglycerides and fasting total HL cholesterol)... Clinical 
Bloods assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4. 
12  Blood pressure, height, weight and waist circumference will also be measured at approximately 12, 18, and 21 months in addition to study visits. 
These will be measured by study RAs. 
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
PAL  X X X  X 
Edinburgh Handedness Inventory  X     
NSSR  X X X  X 
PDQ  X X X  X 
AES  X X X  X 
Structural and functional Imaging       
Shoulder and Hip width13  X     
MRI14  X X X  X 
 
13  Eligibility assessment for MRI scan 
14  MRI assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.  
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Table 22Temporary Pause from DRS+ 
 
1.   Increases from 3 (mild) or below to ratings of 6 or 7 (severe or very severe) on any one 
of the following 3 BPRS49 items: (i) unusual thought content, (ii) hallucinations, and (iii) 
conceptual disorganisation, with a duration criterion of 1 week;  
2.  Significant psychotic exacerbations defined by an increase from 3 or below (for at least 1 
month) on all the BPRS49 3 scales followed by a score of 5 (moderate) on any of the 3-
items plus a 2-point increase on one of the other scales (again with the addition of a 
duration criterion of 1 week) or a rating of 5 on any one of the 3 scales for at least 1 
month.  
3.  An increase in suicidality as defined by a score of 5 or more on the BPRS49 Suicidality 
subscale (i.e., many fantasies about suicide, specific suicide plan, non-lethal attempt) for 
a duration of at least 1 week.   
AND 
4.  A significant decrease in overall functioning as defined by a 20-point drop in SOFAS score 
from the baseline score, maintained for one month.   
 
 
 
 
 
Formatted Table
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OR 
5.  If the above criteria are not met but the participant is considered by their treating 
clinical team to have significantly deteriorated in relation to psychotic symptoms 
compared to baseline, and clinical response is deemed necessary, they may also be 
temporarily paused from the DRS+. 
Table 3  
Reduce Intervention Timeline 
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Abstract 
Anti-psychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 
years. This has been associated with improvements in positive psychotic symptoms and a reduction 
in relapse rates. However, there has been little improvement in functional outcomes for people with 
psychosis. At the same time there is increasing evidence that medications contribute to life 
shortening metabolic and cardio-vascular illnesses. There is also uncertainty as to the role played by 
anti-psychotic medication in brain volume changes.  
Aim: The primary aim of the study is, in a population of young people with first episode psychosis,  
to compare functional outcomes between an anti-psychotic dose reduction strategy with evidence 
based intensive recovery treatment (EBIRT) group (DRS+) and an antipsychotic maintenance 
treatment with EBIRT group (AMTx+) at 24-months follow up. 
Methods: Our single-blind randomized controlled trial, within a specialist early psychosis treatment 
setting, will test the whether the DRS+ group  leads to better vocational and social recovery than, 
the AMTx+ group over a 2-year period in 180 remitted first episode psychosis patients. Additionally, 
we will examine the effect of DRS+ vs AMTx+ on physical health, brain volume and cognitive 
functioning. This study will also determine whether the group receiving DRS+ will be no worse off in 
terms of psychotic relapses over 2 years follow up. 
Results: This paper presents the protocol, rationale and hypotheses for this study which commenced 
recruitment in July 2017. 
Conclusion: This study will provide evidence as to whether an antipsychotic dose-reduction recovery 
treatment leads to improved functioning and safer outcomes in first episode psychosis patients. In 
addition, it will be the first controlled experiment of the effect of exposure to antipsychotic 
maintenance treatment on brain volume changes in this population. 
 
Key words: 
First-episode psychosis 
Functional recovery 
Dose reduction  
Anti-psychotic medication 
Protocol 
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Introduction 
It is over 65 years since antipsychotic medications were introduced and became the mainstay of 
treatment for psychotic illnesses. There has undoubtedly been many benefits of their use in the 
control of symptoms, particularly positive symptoms of psychotic illness, and the reduction of 
relapse rates 1. Despite this, and even with the introduction of second-generation antipsychotic 
medication there has been little indication that people with psychotic illness have returned to 
functional roles in any great number. For example, people diagnosed with psychotic illnesses 2 are 
less likely to complete their secondary education3 and unemployment remains a highly prevalent 
problem associated with the disorder. Loneliness is also a significant issue for young people with 
psychosis, so much so that the onset of psychosis has been characterised as a social network crisis 
which is not ameliorated by current interventions4. In a range of other functional domains, housing 
security,5 physical health6, social relationships and engagement in community7, people with 
psychotic illnesses have worse outcomes than the general population. Antipsychotic medications are 
effective at addressing the symptoms of illness but have little to no success at addressing many of 
the associated problems of the illness8.  Yet, it is these problems that people living with psychosis 
most want addressed9.  
Data from papers published over the last 11 years10,11 have raised the question of how the best 
balance or “sweet-spot” is struck between exposure to antipsychotic medication, symptomatic 
improvement, the minimisation of iatrogenic harm and maximising functional recovery12. The study 
described in this paper seeks to answer this question. 
Background 
After remission from acute symptoms of psychosis is achieved,  most treatments for psychosis have 
focussed upon the prevention of psychotic relapse 13,14. Relapse prevention is a worthy clinical goal, 
due to the potential for distress and other risks associated with acute symptoms,  the direct cost of 
multiple hospital visits associated with relapse15, as well as relapsing courses of psychosis being up 
to 4 times more expensive than non-relapsing courses 16,17. Less focus has been placed on improving 
social and vocational functioning despite these being the primary goals of people who experience 
psychosis9,18. For this reason, functional recovery of people with psychotic illness warrants further 
attention.  In this context we define functional recovery to mean- age appropriate vocational 
functioning, having social outlets, such as friends beyond one’s immediate family and participation in 
one’s community through such activities as voting.  
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The impact of antipsychotic maintenance treatment  
Current evidence based treatment guidelines recommend antipsychotic maintenance treatment for 
2-5 years after a First Episode of Psychosis (FEP) 13, followed by annual review13. In reality, 
maintenance treatment can continue for decades19, partly due to the lack of clarity and evidence 
around how long individuals should receive antipsychotic treatment13,20.   The goal of current 
guidelines is to prevent symptomatic relapse rates in FEP clients21,22. Arguments in favour of ongoing 
maintenance treatment are that: in the absence of medication, risk of  relapse rises significantly, 
episodes of relapse tend to become longer after the initial episode22; response to medication takes 
longer; and approximately 14% at each relapse will not respond to medication23.  While maintenance 
treatment is generally successful at treating positive psychotic symptoms20, the associated side-
effects of antipsychotic medication can be a case of significant harm. These side-effects include 
weight gain 24,25, sexual dysfunction13 and possible contribution to poor functional recovery in 
10people with positive symptom remission.  These associated side-effects can result in poor 
medication adherence26.Adherence to antipsychotic medication is poor in FEP; around 60% of them 
have either non adherence or poor adherence27. Further implications of maintenance treatment 
include metabolic disturbances which lead to increased risks for cardiovascular disease and diabetes 
and the potential for a  20-30 year reduction in life expectancy in people with psychosis28,29,30. 
Metabolic and cardiovascular illness, in large part due to antipsychotic medication28, accounts for 
the majority of this mortality. 31 
 
In addition, maintenance treatment studies3 and meta-analyses32 over the last 10 years have found a 
relationship between exposure to antipsychotic medication and changes in brain volume. Recent 
cross-sectional evidence indicates that antipsychotic medications may produce reductions in grey 
and white matter volumes32 33.  One study in particular found medicated FEP patients to display 
significant cortical thinning in the dorsolateral prefrontal and temporal cortices when compared to 
unmedicated FEP patients, who had cortical thickness measures similar to controls34. Moreover, a 7-
year longitudinal neuroimaging study in FEP showed that loss of brain tissue occurs at the rate of 
0.56 cubic centimetres in patients receiving an average of 4mg/day of haloperidol (dose equivalent) 
over a 1- year period19. Intensity in dose years of antipsychotic treatment was associated with 
reductions in total cerebral volume as well as frontal lobe and white matter volumes. However, 
without a control group this study could not establish whether brain volume reductions are a direct 
consequence of maintenance treatment or are accounted for by other illness-related factors. Given 
that early psychosis is associated with significant loss of grey matter volume over time relative to 
healthy controls35 , there is a possibility that medication discontinuation could reduce this loss, or 
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preserve brain changes such that they are comparable to neurotypical same-age peers. Further, 
some evidence suggests that antipsychotic treatment may alter cerebral function in FEP and the 
impact of a dose reduction strategy on functional connectivity of resting-state neural networks is 
currently unknown 34,36-38. Additionally, cognitive function may be adversely affected by maintenance 
treatment. Three naturalistic studies in prodromal and established schizophrenia groups show a 
relationship between level of exposure to antipsychotic medication and decline in cognitive function 
over time39-41. Furthermore, meta-analytic evidence suggests that the processing speed impairment 
observed in psychotic disorders is significantly associated with chlorpromazine equivalent daily 
dose.42 As symptom intensity or persistence may confound the relationship between cognitive 
performance and antipsychotic dose, randomised controlled trials are required.  
Two small double-blind placebo-controlled crossover studies of inpatients with schizophrenia (N=27 
and N=19, respectively) found that antipsychotic medication was associated improved cognitive 
performance compared with placebo43,44. A recent guided anti-psychotic discontinuation RCT in FEP 
(N=53) found that cognitive function improved in remitted FEP clients who received guided 
discontinuation compared with those who received maintenance treatment over a five month follow 
up period40. Previous research has also shown that adherence to high/standard-dose maintenance 
treatment is associated with poorer psychosocial functioning early in the course of recovery, 
suggesting that a strong focus on high-dose maintenance medication may interfere with long-term 
recovery 10. This is also consistent with the follow-up results from the Episode II trial45.  
A recent critical review also proposed that although anti-psychotic maintenance may be efficacious 
in mid-term treatment of psychosis, there is a paucity of evidence supporting the efficacy of this 
treatment approach in the long-term, this supports further inv stigation of a dose reduction 
strategy12.  
 
Is dose reduction the answer?  
The negative impacts of long-term maintenance have raised the question of whether dose reduction 
might be associated with better outcomes for individuals affected by psychotic disorders. Recent 
evidence showing that functioning improves with a strategy to reduce the dose of antipsychotic 
medication suggests that functional recovery may be suppressed by long-term exposure to 
antipsychotic medication10,46. A meta-analysis of RCTs of antipsychotic treatments in FEP clients 
showed that approximately 40% of placebo-treated FEP clients had not relapsed at 1-year follow 
up32. Subsequently, one recent RCT revealed that, when compared with continuous maintenance 
treatment, the discontinuation of maintenance treatment in FEP led to improved recovery at 7 years 
follow up10. Importantly, this occurred in the absence of intensive psychosocial treatments that may 
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hasten improvement of functioning and prevent relapse32. Thus, recovery may be enhanced or 
hastened if a dose reduction strategy were combined with intensive evidence based psychosocial 
interventions. These findings suggest that, despite current guidelines, FEP clients may not require 
maintenance treatment for the initial recommended two-year minimum period to attain recovery 
and prevent relapse. Indeed, previous research has shown that it is early functional recovery rather 
than symptomatic recovery that predicts functional recovery at 7.5 years 47. 
Arguably, patient non-adherence48, and planned discontinuation of maintenance treatment both 
pose risks for relapse after FEP47. However, reduction in symptoms does not automatically translate 
into functional gains. Prioritising relapse prevention without also giving full consideration to the 
implications for functional recovery may compromise the long-term outcomes most valued by those 
who experience the illness 9,49 .  
Management of relapse risk therefore, should be balanced with a focus on functional recovery and 
the costs of long-term continuous maintenance treatment, including probable enhancement in 
functioning32. A promising balanced approach to treatment includes a dose reduction strategy, 
combined with intensive and recovery-focussed psychosocial treatments with vigilant monitoring for 
early signs of relapse50.  
Supplementary to a dose reduction strategy, the use of an evidence-based intensive recovery 
treatment (EBIRT) should be employed to improve likelihood of overall functional outcomes. In the 
present study, EBIRT combines two previously trialled interventions. These interventions are 
Individual Placement and Support (IPS) for vocational recovery and CBT for Relapse Prevention. IPS 
in addition to specialist FEP treatment has produced significantly better outcomes in gaining 
employment, hours worked, jobs acquired, and longevity of jobs compared to specialist FEP 
treatment alone 45,51.  CBT for relapse prevention combined with specialist FEP treatment when 
compared with specialist FEP treatment alone45, led to a significant reduction in relapse rates at 7-
months follow up in FEP clients who met remission on positive symptoms. This effect was sustained 
at 1 year, and relapse rates were kept to historically low levels beyond this time point (30% at 2.5 
years) 45,52. However, these differences were no longer significant at 30-month follow-up.  
Importantly, 83% of clinicians providing care to people experiencing FEP would support a carefully 
monitored dose reduction strategy after patient relapse, and believe this would improve the quality 
of life of their clients53. This further supports the acceptability of a dose reduction strategy, 
particularly in a FEP setting48,54,55 
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Aims 
The primary aim of the study is to compare functional outcomes between a dose reduction strategy 
with EBIRT group (DRS+) and an antipsychotic maintenance treatment with EBIRT group (AMTx+) at 
24-months follow up.  
This study has a range of secondary aims:  
1. To compare physical health and metabolic profiles between DRS+ and AMTx+ at 24-months 
follow up. 
2. To compare grey and white matter volume between DRS+ and AMTx+ at 24-months follow 
up. 
3. To compare brain activity during resting-state between DRS+ and AMTx+ at 24 months 
follow up*. 
4. To compare cognitive functioning between DRS+ and AMTx+ at 24-months follow up. 
5. To compare remission and relapse rates between DRS+ and AMTx+ at 24-months follow up. 
*This is a largely exploratory aim, however based on the limited literature in this area we hypothesis 
that the DRS+ group would display greater resting state functional connectivity than the AMTx+ and 
healthy control groups 
Primary hypothesis 
H1: Remitted FEP patients randomised to DRS+ will achieve superior social and vocational 
functioning at 24-months follow up, compared with remitted FEP patients randomised to AMTx+. 
Secondary hypotheses 
H2: Participants randomised to DRS+ will have less reduction in grey and white matter volume than 
participants randomised to AMTx+ at 24-months follow up.  
H3: Degree of antipsychotic exposure will be negatively associated with grey and white matter 
volume at 24-months follow up. Further, it is expected that change in neural activity during resting 
state will differ significantly between the DRS+ and AMTx+ groups at 24-months follow-up.  
H4: Participants randomised to DRS+ will have better cognitive functioning compared to participants 
randomised to AMTx+ at 24-months follow up.  
H5: Participants in the AMTx group will have experienced fewer relapses at 24-months follow up.  
H6: Participants randomised to DRS+ will have significantly better metabolic indices (defined as 
being within normal parameters) and an improved physical health status at 24-months follow up. 
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Ethical approval 
This study was approved by the Melbourne Health Human Research Ethics Committee 
(HREC/16/MH/309) in February 2017 and began recruiting participants in July 2017.  The trial is 
registered on the Australian and New Zealand Clinical Trials Registry (12617000870358).  
Methodology 
Study Design 
This study is a single blinded non-placebo randomised controlled trial where research assistants are 
blinded to treatment allocation.  
Study Setting 
This study will be conducted at the Early Psychosis Prevention and Intervention Centre (EPPIC), a 
sub-program of Orygen Youth Health (OYH). OYH is a youth public mental health service in 
Melbourne for 15 to 25-year-olds (inclusive). EPPIC is a comprehensive specialist early psychosis 
program that provides outpatient case management, psychosocial intervention and psychiatric 
treatment. OYH is co-located with Orygen, the National Centre of Excellence in Youth Mental Health 
and the Centre for Youth Mental Health, The University of Melbourne. EPPIC provides up to 2 years 
of specialised care after which clients are transferred to another service depending upon the level of 
care required. A proportion of clients receive follow-up care within primary care settings, while 
others may continue to require case-management and specialist care and are therefore transferred 
to the adult mental health service.  The Reduce Trial will embed specific resources within EPPIC, 
including a proportion of one psychiatry registrar position, a Vocational Support Worker and a 
number of specialist Reduce trial case managers, who will provide the medical oversight, the 
vocational recovery support and the clinical case management for trial participants, respectively.   
Inclusion and Exclusion Criteria  
Inclusion and Exclusion Criteria have been designed to reflect ‘real-world’ characteristics of young 
people presenting to clinical settings with a FEP.  
Inclusion Criteria: (i) Current client of EPPIC; (ii) A confirmed diagnosis of first episode of a DSM 556 
psychotic disorder or mood disorder with psychotic features56,57; (iii) Aged 15-25 years (inclusive); 
(iv) ≥ 3 months of remission on positive symptoms of psychosis in the first year of antipsychotic 
treatment (participants must currently be taking their prescribed anti-psychotic medication) at EPPIC 
(a score of  ≤3 (mild) on the hallucinations, unusual thought disorder, conceptual disorganisation, 
and suspiciousness subscale items of the Brief Psychiatric Rating Scale (BPRS)58 for the past two 
weeks and a score ≤3 on the hallucinations, unusual thought content, conceptual disorganisation, 
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and suspiciousness subscales of the BRPS58 for the past 3 months based on a systematic clinical file 
review and collateral information collected from the participant’s treating team in EPPIC (as 
needed); (v) Low suicidality defined as a score of 4 or below on the BPRS58 sustained for the past 1-
month period prior to baseline; (vi) The young person is willing for a caregiver to be informed about 
the study and will have at least weekly contact with their caregiver; (vii) Ability to provide written 
informed consent. 
Exclusion Criteria: (i) A documented history of an intellectual disability or IQ <70; (ii) Inability to 
converse in or read English; (iii) Women who are currently pregnant or breastfeeding; (iv) 
Neurological disorder (illness of the brain, nerves or spinal cord which could not better explain the 
presence of psychosis).  
Recruitment, Consent, and Enrolment   
Participants will be recruited into the trial through a number of strategies- including regular case 
review discussions between the Reduce research assistant (RA) and EPPIC Consultants, direct 
referral to Reduce from EPPIC Clinicians and through the RA attending regular EPPIC team meetings 
to discuss ongoing eligibility of clients nearing three months of psychotic remission. Potential 
participants are then approached to take part in the trial by either the RA, Reduce registrar or case 
manager. They are given ample time to consider the option to take part in Reduce and are 
encouraged to discuss this with their family, local doctor and other supports. Before being enrolled 
in the study all participants will provide written and informed consent. In the case of minors, their 
parent or legal guardian will also be required to provide written and informed consent. After the 
consent process is complete, a Core Baseline assessment is administered by the research assistant. 
Eligibility is assessed, using the BPRS58 and the SCID-RV57. Participant medical files and EPPIC clinical 
files will also be used for collateral information to confirm eligibility  
Method of Assigning participants to Treatment Groups and Randomisation 
An independent statistician will organise the randomisation. The randomisation will be stratified by 
sex at birth (male vs. female) and baseline diagnosis (affective vs. non-affective) as these 
characteristics are associated with key outcomes in this study and any chance imbalances may bias 
the analysis. Participants will be allocated to either the EBIRT (AMTx+) or EBIRT (DRS) treatment 
groups using randomly permuted blocks of varying size within each stratum, to maintain 
approximately equal group sizes over time. The randomisation sequences will be concealed within a 
secured password protected website. On obtaining informed consent of a new participant, the 
delegated research team member will access this website and enter the participant’s details. The 
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delegated research team member will then inform the treating team the randomisation outcomes 
who will then inform and discuss this with the participant.   
A client identification (ID) number will be allocated to clients approached to ascertain their eligibility 
to participate in the study. Each eligible participant will be allocated to a unique and sequential 
randomization number. 
Healthy Control Group 
Because the age range of participants covers a time of significant neurodevelopment, 40 healthy 
controls aged 15-25 years (inclusive), living in the EPPIC catchment, with no history of mental illness, 
neurological condition or antipsychotic medication treatment will also be recruited. They will 
undergo MRI scanning, be cognitively assessed and have physical health indicators measured (except 
bloods) at the same four time points as the DRS+ and AMTx+ groups (baseline, 9-months, 15-months 
and 24-months). This will provide objective control data to determine whether there are physical 
health, brain volume and neural activation or cognition changes and if they are related to illness, 
medication or typical development. 
Outcome Measures 
The primary outcome measure is the Social and Occupational Functioning Scale59 (SOFAS) at 24 -
months. In addition to the primary outcome measure, a number of measures will assess physical 
health and metabolic profiles, brain volumes/activity, cognitive functioning and remission and 
relapse rates at 24-months.  
Secondary Endpoint measures 
Symptomatology 
Remission and relapse of positive symptoms will be assessed using the expanded Brief Psychiatric 
Rating Scale60 (BPRS) in treatment groups only. Remission of negative symptoms will be assessed 
using the Scale for Assessment of Negative Symptoms (SANS)61. The a priori clinically significant 
degree of difference on duration of relapse is 7 days, in accordance with published duration 
criteria52.  
Neurocognitive assessments 
A battery of neurocognitive tests including the Brief Assessment of Cognition in Schizophrenia62 
(BACS App) will be used to assess cognitive functioning in all groups, including healthy controls. 
Further detail of the full neurocognitive battery can be found in the Schedule of Assessments (Table 
1).  
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INSERT TABLE 1 ABOUT HERE 
 
Physical health assessments 
Blood pressure, weight, height and waist circumference will also be recorded in all groups including 
healthy controls.  
Haematological investigations 
Physical health will be measured by clinical blood analysis evaluating fasting glucose, haemoglobin 
A1C, triglycerides and Total HL cholesterol in the treatment groups only. 
Brain imaging 
Brain volume will be quantified in both treatment groups and healthy controls by high-resolution 
magnetic resonance imaging (MRI).  In addition to structural MRI, functional resting state data will 
also be collected.  
Study Intervention  
Intervention 
After randomisation and allocation to one of the two conditions, all participants will commence the 
intensive EBIRT phase in which they will attend up to twice weekly individual therapy and vocational 
support sessions until Month 9.  
Evidence-Based Intensive Recovery Treatment (EBIRT)  
EBIRT combines two well-validated and manualised psychosocial interventions: Individual Placement 
and Support (IPS) for vocational recovery and Cognitive Behaviour Therapy (CBT) for Relapse 
Prevention. EBIRT will be delivered in two phases; a 9-month intensive phase which entails up to two 
sessions of individual therapy (one CBT sessions and one IPS session) per week for 9-months. All 
participants will receive 9 months of the EBIRT intensive phase. This will followed by a 6-9 month 
(dependent on tenure remaining in service) - maintenance/monitoring phase in which individual 
therapy sessions will be delivered every 4-6 weeks.  
 The first component of EBIRT is CBT. This will be provided by a therapist trained in CBT and is 
comprised of six or more modules of therapy delivered over the 9-month intensive period. The six 
phases of EBIRT intervention include: (1) initiation of vocational intervention (2) formulation and 
agenda setting; including vocational goal setting; (3) engagement and assessment for recovery and 
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risk for relapse; (4) psychoeducation with a focus on relapse; (5) early warning signs and relapse 
planning – will also involve family members with participant’s consent; and, treatment and progress 
review (6). Additional optional modules may be drawn upon depending on case formulation and 
clinical determination in collaboration with the participant include: substance abuse, stress 
management, and co-morbid anxiety and depression at the participant or clinician discretion.  The 
second component of EBIRT is IPS. This will focus on (a) focussed upon competitive employment, 
education or training as an outcome; and (b) focussed upon immediate job/education searching and 
will be delivered by a Youth Specialist Vocational Consultant.  In tandem with EBIRT, participants will 
be randomly assigned following baseline assessment to either the DRS+ or AMTx treatment 
conditions.  
DRS will comprise a 9-month EBIRT phase (DRS+). The comparator group will receive AMTx and 
EBIRT (AMTx+). The EBIRT intervention will be the same in both groups. The AMTx group treatment, 
including medication prescription will be in accordance with published treatment guidelines. The 
Reduce trial clinicians will collect data on frequency, content and duration of therapy sessions in 
order to measure treatment complianc  for the duration of the 15-18 month EBIRT treatment.  
 
At Month 9, all participants will transition into the lower intensity monitoring phase of EBIRT in 
which they will attend individual therapy sessions with their Reduce case manager every 4-6 weeks 
for a minimum of 6 months. All participants will receive at least 15 months of total Reduce 
treatment and a maximum of 18 months, depending on how long their psychotic symptoms take to 
stabilise upon entry into EPPIC. This means that some participants will receive a total of 24 months 
of EPPIC treatment whereby, some participants will receive 27 months total EPPIC treatment. 
Participants are entitled to the full EPPIC treatment package throughout this time and can have the 
frequency of appointments with EPPIC team increased should there be a clinical indication to do so.  
Differences in EPPIC treatment will be recorded. 
Dose Reduction Strategy (DRS+) group 
Participants who are randomised to this arm of the trial will be offered a gradual dose reduction of 
their antipsychotic medication at their next medical review after randomisation. Medication will be 
tapered under close medical supervision over 3-months after allocation to the DRS group to 
minimise the risk of relapse due to abrupt discontinuation. The rate of tapering will be a 25% dose 
reduction (or as near to 25% as the medication allows) of the pre-reduction dose every month for 3 
months, until the participant reduces a dose that is considered clinically safe, whereby some 
participants will completely cease taking the antipsychotic medication. This will see some variation 
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in participants’ reduction schedule. All data on the rate of dose reduction will be collected by the 
Reduce clinicians to measure the variations in participant treatment.  
Antipsychotic Maintenance Treatment (AMTx) group 
Participants will be prescribed medication as clinically indicated, concordant with the Australian 
Clinical Practice Guidelines for FEP54,55. These guidelines recommend the use of the lowest effective 
dose of atypical antipsychotics.  
All trial participants will have access to all components of treatment at EPPIC, including psychiatric 
care, case management, psychosocial program, acute inpatient care and outreach as clinically 
indicated.58,61,62 
Safety Measures 
Participants will be managed within the EPPIC clinic at OYH. Participants will be monitored by the 
treating team. Clinical appointments can be held more frequently when clinically indicated.  In 
addition, the BPRS58 and SOFAS59 scales will administered weekly by the participant’s EBIRT Clinician 
to assess for participant symptomatic relapse, and to measure the acceptability and safety of the 
prescribed dose. The SOFAS will measure functioning during the 9-month intensive phase. These 
safety assessments will continue to occur every 4-6 weeks up until Month 24 and administered by 
either the EBIRT Clinician or the Research Assistant.  
Temporary Pause or Complete Discontinuation from DRS+ 
In the event of symptomatic relapse or worsening of symptoms, and the participant meeting the 
criteria for relapse described in Table 2, the participant’s dose reduction treatment may be 
temporarily paused.  
Table 2 presents the criteria used to define psychotic relapse and will result in a temporary pause 
from the DRS+ treatment. These relapse criteria have been developed with the aim of reflecting 
‘real-world’ relapse of FEP.  Participants must satisfy either Criteria 1, 2 or 3 in combination with 4 to 
meet relapse criteria.58 There is also a ‘fail-safe’ option should stopping the DRS be clinically 
indicated.  
*TABLE 2 HERE* 
Participants will be monitored by their treating team and study personnel and regularly assessed for 
relapse, psychotic exacerbations and functioning.  
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In the event of a temporary pause in the dose reduction strategy the clinical team will decide 
whether the participant should restart their antipsychotic medication or increase their dose. Any 
changes made will be in consultation with the participant.  
If antipsychotic medication is recommenced or if the dose is increased, it will be titrated up until an 
effective dose is reached. Titration will occur at a pace appropriate to the individual's clinical 
presentation and should allow adequate time for a response at each dosing interval. In this case, 
psychiatry registrars will discuss appropriate dose with treating consultants and ensure any changes 
are documented. If the participant fails to achieve satisfactory recovery defined by persistence of 
severe psychotic symptoms whilst consistently meeting criteria described in Table 2 for 3 months 
following the initial relapse, or if they become pregnant during the study they will be completely 
discontinued from DRS+, whilst still remaining in EPPIC and receiving EBIRT. These participants will 
also be invited to continue with the research assessments and included in intention-to-treat 
analyses.  
Table 3 outlines the study schema 
*TABLE 3 HERE*  
Participants discontinued from the AMTx+ group will continue to receive treatment in accordance 
with the Australian Clinical Practice Guidelines. If they wish they may continue with EBIRT and the 
research assessments. These participants will also be included in intention-to-treat analyses. 
Withdrawal Criteria 
A participant will be withdrawn from the study if they choose to no longer participate in the Reduce 
study voluntarily, A participant will be considered ‘withdrawn’ from the study in cases where all 
involvement in the trial is ceased and no further follow up is enacted 
Blinding  
The delegated study statistician will be blind to treatment allocation. Research assistants (RAs) will 
also be blind to treatment allocation. The study RAs will be kept blind to treatment allocation using 
the following processes: (a) regular reminders will be sent to clinical staff at EPPIC, regarding the 
importance of the blind; (b) at the start of each research interview the RA will remind the 
participants of the importance of the blind; (c) the RA will have restricted access to participants’ 
medical records. The unblinded Project Manager will have access to the participant’s medical 
records and will retrieve and provide study RA’s with any information that is required (i.e. for 
screening). Because the extent and rate of dose tapering in each individual case requires clinical 
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tailoring in response to preceding dose reductions, it is not feasible to utilise a placebo control, so 
medication treatment will be open-label, with medications chosen by EPPIC psychiatrists. 
Statistical methods and determination of sample size 
Data analysis will be conducted at the completion of the study (24-months from last patient first 
visit) and as such there will be no interim analyses conducted. The primary outcome is SOFAS score 
at two-year follow-up. Calculations of effect size are based on detecting a two-year follow-up effect 
size of d=0.505, based on our previous relapse prevention studies which found a group difference of 
this magnitude on the SOFAS at two-year follow-up. Power is set at 0.85, α = .05 (two-tailed). The 
estimated sample size is 144 (n=72 per group). To accommodate an attrition rate of 20%, the target 
sample size will be 180, or 90 participants per treatment group. Differences on social and vocational 
functioning measures will be examined using mixed model repeated measures and intention-to-treat 
analysis. Between-group differences on vocational status will be examined using logistic regression. 
Patterns of missing data and missing data mechanisms will be investigated using two approaches; 
firstly, Little’s missing completely at random (MCAR) test will be used to assess the degree to which 
the data are likely to meet the MCAR mechanism; secondly, prediction of missingness at each of the 
assessment points will be undertaken using binary logistic regression, with a range of baseline 
sociodemographic, clinical, and psychopathology variables used to predict the presence or absence 
of a particular assessment.  Likelihood techniques will be used to address missing data. The same 
statistical models described above will be used to characterise the effects of treatment regimen on 
grey and white matter volumes. Flexible factorial models will be used to estimate significant within-
and between-group activation effects at the whole brain level (using F-tests) to determine the 
effects of treatment regimen on brain function. A cluster-based permutation approach will be used 
to identify significant differences satisfying a Family Wise Error rate of .05. Age and sex assigned at 
birth will be controlled for in all analyses. 
Data Safety Monitoring Board  
A Data Safety Monitoring Board will be established in accordance with ICH-GCP Guidelines and the 
NHMRC’s 2018 guidelines on DSMBs.  
Trial Status  
The study commenced enrolling participants in July 2017. Enrolment is continuing at the time of 
manuscript submission. The report of the study findings is expected in 2024.  
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Table 1  
Outline of Schedule of Assessments  
 
Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Informed Consent4 X      
Inclusion/Exclusion Criteria X      
Demographics X  X X  X 
Medical & Psychiatric History  X     
Pregnancy (urine)5 X   X  X 
 
1  Core Baseline assessments may be conducted over a number of visits to allow for ‘real-world’ scenarios however, must be completed prior to 
randomisation.  
2  Non-Core Component Baseline assessments may be conducted over a number of visits to allow for ‘real-world’ scenarios and can be completed up to 3 
weeks after randomisation.  
3  Telephone contact every 6 weeks from Month 9-24 to check discontinuation/withdrawal criteria.  
4  Informed consent can be obtained up to 21 days prior to baseline.  
5  In addition to conducting urine pregnancy tests at each baseline and 24-month assessments, participants will also be asked to indicate whether they are 
pregnant or not during 9-month, 15-month assessments and telephone follow-ups. 
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Concomitant Med. Review6  X X X X X 
Treatment Allocation       
Randomisation X      
Diagnosis       
SCID5-RV (Modules A & B)  X   X  X 
Intervention       
Participants in DRS+7       
EBIRT8         Post intervention Follow up  
 
6  To maintain blinding of RAs, EBIRT clinicians will review medication adherence weekly (every second session) during the EBIRT intensive phase and 
every session during the EBIRT maintenance phase. EBIRT clinicians will also check concomitant medications every 6 weeks during the intervention phase 
(up to minimum of 15 months).  
7  Reduce antipsychotic medication dose by 25% every month for 3 months as clinically indicated. 
8  EBIRT intensive phase: Twice weekly individual therapy sessions to month 9, maintenance/monitoring phase 4-6 weeks individual therapy for a 
minimum of 6 months. A checklist recording details and items covered in of the EBIRT (CBT) Session will be completed every session by the Clinician and 
entered directly into the eCRF. The IPS Worker will also complete a checklist recording items covered in every session and enter this in to the eCRF. This 
data will be used to assess fidelity of EBIRT.   
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Medication Compliance       
Clinician’s compliance rating5  X X X   
MARS5  X X X  X 
Medication side effects       
LUNSERS  X X X  X 
Symptomatology       
BPRS9 X  X X X X 
SANS  X X X  X 
DASS-21  X X X X X 
CDSS  X X X  X 
IPASE  X X X  X 
Functioning & Quality of Life       
SOFAS8  X X X X X 
Vocational functioning  X X X X X 
 
9  In addition to assessment time-points and telephone follow-up, the BPRS and SOFAS will be measured weekly during the intensive phase and at therapy 
sessions during the maintenance phase for purposes of discontinuation criteria.   
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
WHOQoL-BREF  X X X  X 
ULCALS  X X X  X 
MHCS  X X X  X 
The Self-efficacy Scale  X X X  X 
BPNS   X X X  X 
Daily functioning and affect       
SEMA10  X X X  X 
Pre-morbidity and Illness       
NOS  X     
Trauma       
CTQ  X     
Metabolic monitoring       
Clinical Bloods11  X X X  X 
 
10  SEMA will be used to deliver electronic surveys (to be administered directly after the baseline and follow up assessments (visits 1-4) at 8 time 
points per day in the waking hours of each participant for a period of 7 days. Only participants who have smartphones will complete these surveys.  
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
Blood pressure, height, weight and 
waist circumference12 
 X X X  X 
Substance Use       
AUDIT  X X X  X 
 ASSIST   X X X  X 
Neurocognitive       
WRAT-4  X     
BACS  X X X  X 
ER-40  X X X  X 
The Hinting Task  X X X  X 
                                                                                                                                                                                                                                                                                                    
11 
 Clinical bloods will involve testing for fasting glucose, haemoglobin A1C, fasting triglycerides and fasting total HL cholesterol.. Clinical Bloods assessment 
to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4. 
12  Blood pressure, height, weight and waist circumference will also be measured at approximately 12, 18, and 21 months in addition to study visits. 
These will be measured by study RAs. 
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Visit 1 
Baseline  
Visit 2 Visit 3 
End of Intervention 
 Visit 4 
End of Study 
 
Core Baseline1 
Day -21 to 1 
Non- Core 
Baseline2 
Day 1 to Day 
21 
9-month 
 + 3 months 
15-18 month  
+ 3 months 
Phone follow up3 
± 7 days 
24-month 
± 28 days 
Assessment       
PAL  X X X  X 
Edinburgh Handedness Inventory  X     
NSSR  X X X  X 
PDQ  X X X  X 
AES  X X X  X 
Structural and functional Imaging       
Shoulder and Hip width13  X     
MRI14  X X X  X 
 
13  Eligibility assessment for MRI scan 
14  MRI assessment to be completed within two weeks of randomisation and within two weeks of Visits 2 to 4.  
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Table 2Temporary Pause from DRS+ 
 
1.   Increases from 3 (mild) or below to ratings of 6 or 7 (severe or very severe) on any one 
of the following 3 BPRS49 items: (i) unusual thought content, (ii) hallucinations, and (iii) 
conceptual disorganisation, with a duration criterion of 1 week;  
2.  Significant psychotic exacerbations defined by an increase from 3 or below (for at least 1 
month) on all the BPRS49 3 scales followed by a score of 5 (moderate) on any of the 3-
items plus a 2-point increase on one of the other scales (again with the addition of a 
duration criterion of 1 week) or a rating of 5 on any one of the 3 scales for at least 1 
month.  
3.  An increase in suicidality as defined by a score of 5 or more on the BPRS49 Suicidality 
subscale (i.e., many fantasies about suicide, specific suicide plan, non-lethal attempt) for 
a duration of at least 1 week.   
AND 
4.  A significant decrease in overall functioning as defined by a 20-point drop in SOFAS score 
from the baseline score, maintained for one month.   
OR 
5.  If the above criteria are not met but the participant is considered by their treating 
clinical team to have significantly deteriorated in relation to psychotic symptoms 
compared to baseline, and clinical response is deemed necessary, they may also be 
temporarily paused from the DRS+. 
Table 3  
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Reduce Intervention Timeline 
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